drug
CANAGLIFLOZIN
Marketedupdated 5mo agoby Johnson & Johnson Innovative Medicine
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3indications
investigational
Type 2 Diabetes
all catalysts(2)
Trials studying CANAGLIFLOZIN
- phase4Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus
- phase4Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus
- phase4Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus
- phase3Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)
- phase3Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
- phase3Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)
- phase3Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes
- —A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 14, 2027
288 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (12)
- Aug 26, 2029patentUS 7943582*PED2.9y
- Aug 26, 2029patentUS 7943582*PED2.9y
- Feb 26, 2029compositionUS 79435822.4y
- Feb 26, 2029compositionUS 79435822.4y
- Jun 3, 2028patentUS 8513202*PED1.7y
- Jun 3, 2028patentUS 8513202*PED1.7y
- Jan 14, 2028patentUS 7943788*PED1.3y
- Jan 14, 2028patentUS 7943788*PED1.3y
- Dec 3, 2027compositionUS 85132021.2y
- Dec 3, 2027compositionUS 85132021.2y
- Jul 14, 2027compositionUS 7943788288d
- Jul 14, 2027compositionUS 7943788288d
FDA exclusivities (4)
- Jun 18, 2028PEDPediatric (6mo bonus)1.7y
- Jun 18, 2028PEDPediatric (6mo bonus)1.7y
- Dec 18, 2027NPPNew Product (3y)1.2y
- Dec 18, 2027NPPNew Product (3y)1.2y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 53m ago
Found something off?
comments(0)
5-min edit window · permanent after that